126 related articles for article (PubMed ID: 38887930)
1. Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer.
Lee JJ; Kearney JF; Trembath HE; Hariharan A; LaBella ME; Kharitonova EV; Chan PS; Morrison AB; Cliff A; Meyers MO; Kim HJ; Rashid NU; Peng XL; Yeh JJ
Ann Surg; 2024 Jun; ():. PubMed ID: 38887930
[TBL] [Abstract][Full Text] [Related]
2. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
3. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
[TBL] [Abstract][Full Text] [Related]
4. Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes.
Peng XL; Kharitonova EV; Xu Y; Kearney JF; Luan C; Chan PS; Hariharan A; McCabe IC; Leary JR; Morrison AB; Trembath HE; LaBella ME; Herera Loeza SG; Cliff A; Kim HJ; Belt BA; Panni RZ; Linehan DC; Damrauer JS; Iuga AC; Kim WY; Rashid NU; Yeh JJ
bioRxiv; 2024 May; ():. PubMed ID: 38798565
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
6. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
7. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
[TBL] [Abstract][Full Text] [Related]
8. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
11. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
12. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma.
Qiao G; Fong ZV; Bolm L; Fernandez Del-Castillo C; Ferrone CR; Servin-Rojas M; Pathak P; Lau-Min K; Allen JN; Blaszkowsky LS; Clark JW; Parikh AR; Ryan DP; Weekes CD; Roberts HM; Wo JY; Hong TS; Lillemoe KD; Qadan M
Ann Surg; 2024 Jul; 280(1):118-125. PubMed ID: 37830225
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
14. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma.
Wu MY; Shen M; Xu MD; Yu ZY; Tao M
Gland Surg; 2020 Dec; 9(6):2125-2135. PubMed ID: 33447563
[TBL] [Abstract][Full Text] [Related]
17. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
18. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.
Tong YT; Wang H; Wei D; Prakash LR; Kim M; Tzeng CD; Lee JE; Rashid A; Koay EJ; Wolff RA; Maitra A; Katz MH; Wang H
Pancreatology; 2021 Oct; 21(7):1378-1385. PubMed ID: 34429247
[TBL] [Abstract][Full Text] [Related]
19. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
20. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma.
da Costa WL; Tran Cao HS; Gu X; Massarweh NN
Ann Surg; 2022 Mar; 275(3):415-421. PubMed ID: 35120060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
